In the original article, there was a mistake in [Table 2](#T2){ref-type="table"} "Key published studies demonstrating the safety and tolerability of DPP-4 inhibitors" as published. Unfortunately, two of the citations were transposed in the table. The correct citation for the SAVOR-TIMI trial is Scirica et al. (2013): Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317--1326 (ref 127), while the correct citation for the TECOS trial is Green et al. (2015): Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373: 232--242, 2015 (ref 126). The corrected [Table 2](#T2){ref-type="table"} appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

###### 

Key published studies demonstrating the safety and tolerability of DPP-4 inhibitors.

  **Inhibitor**                              **Alogliptin**                    **Linagliptin**                       **Saxagliptin**                    **Sitagliptin**                    **Vildagliptin**
  ------------------------------------------ --------------------------------- ------------------------------------- ---------------------------------- ---------------------------------- ----------------------------------
  **POOLED SAFETY ANALYSES**                                                                                                                                                               
  References                                 Prately et al. (119)              Lehrke et al. (120)                   Hirshberg et al. (121)             Engel et al. (122)                 Schweizer et al. (123)
  Study                                      6 phase 2 and 3 clinical trials   22 phase 1, 2 and 3 clinical trials   20 phase 2 and 3 clinical trials   25 phase 2 and 3 clinical trials   38 phase 2 and 3 clinical trials
  Number                                     2,366                             7,400                                 9,156                              14,611                             12,326
  Comparator                                 Placebo                           Placebo                               Placebo or active comparator       Placebo or active comparator       Placebo or active comparator
  Duration                                   12--26 weeks                      \< 2--104 weeks                       4--206 weeks                       12--104 weeks                      12--104 weeks
  **CARDIOVASCULAR SAFETY OUTCOME TRIALS**                                                                                                                                                 
  References                                 White et al. (124)                Rosenstock et al. (125)               Scirica et al. (127)               Green et al. (126)                 --
  Trial name                                 EXAMINE                           CARMELINA                             SAVOR-TIMI                         TECOS                              --
  History of CV disease (%)                  !00 (ACS)                         57                                    78                                 100                                --
  Number                                     5,380                             6,979                                 16,492                             14,671                             --
  Comparator                                 Placebo                           Placebo                               Placebo                            Placebo                            --
  Follow-up (y)                              1.5                               2.2                                   2.1                                3.0                                --
  MACE HR (95% CI)                           0.96 (upper, 1.16)                1.02 (0.89; 1.17)                     1.00 (0.89; 1.12)                  0.98 (0.88; 1.09)                  --

*Pooled safety analyses examined patient-level safety data from phase 1--3 clinical trials in patients with T2DM. Cardiovascular safety outcome trials included patients with T2DM and either established CV disease or multiple CV risk factors (and albuminuria or impaired renal function in CARMELINA). The primary endpoint in the CV safety outcome trials was a composite of CV death, non-fatal myocardial infarct, and non-fatal stroke (and unstable angina requiring hospitalization in TECOS). Note: there is no equivalent large CV safety outcome trial with vildagliptin*.

*ACS, acute coronary syndrome; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MACE, major adverse cardiovascular events*.
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